Michael Anderson is a Psychiatry physician. ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1672 Lakeshore Ct Apt C
Homewood, AL 352097129
Telephone
478-714-6398Provider last certified this registry record 10 Apr 2023.
Clinical trials
- A Safety and Efficacy Study of the Birmingham Hip Resurfacing System
Sponsor: Smith & Nephew, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Organogenesis Inc.Program year20241 payment
- Otsuka America Pharmaceutical, Inc.Program year20241 payment
- Otsuka America Pharmaceutical, Inc.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
99%SSRI21.2%Trazodone Hcl38%Fluoxetine Hcl16%Citalopram Hbr13%Escitalopram Oxalate12%Sertraline Hcl10%Paroxetine Hcl10%Fluvoxamine Maleate2%Part D<11 patientsAtypical Antipsychotic17.8%Quetiapine Fumarate22%Aripiprazole20%Olanzapine14%Risperidone12%Rexulti8%Ziprasidone Hcl6%Invega Sustenna5%Lurasidone Hcl3%Olanzapine Odt3%Vraylar2%Abilify Maintena2%Clozapine2%Part D<11 patients+ 20 more classes in this area
Cardiovascular
1%Beta blocker0.6%Propranolol Hcl100%Part D<11 patientsalpha-Adrenergic Blocker0.3%Prazosin Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2000–2000 per NIH RePORTER. The latest:
- REAGENTS FOR IDENTIFICATION OF ANTIGEN-SPECIFIC T CELLS
Southern Biotechnology Associates, Inc.
FY2000$106,000R41AI047624
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Philip Scheltens
Inserm
Rafael Tabarés‐Seisdedos
Universitat de València
Nick C. Fox
UK Dementia Research Institute
Perminder S. Sachdev
Department of Health and Aged Care
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”